2nd Jan 2025 14:29
Cizzle Biotechnology Holdings PLC - London-based life sciences company engaged in developing a blood test for the early detection of the different forms of lung cancer - Appoints Founder & Non-Executive Director Dawn Coverley as chief scientific officer, effective immediately. Says the new role replaces her position as a NED and accelerates its global licensing and partnership strategy to bring its non-invasive, cost effective, CIZ1B biomarker lung cancer blood test to market in 2025. Read More
